Cilastatin
- Generic Name
- Cilastatin
- Brand Names
- Primaxin, Recarbrio
- Drug Type
- Small Molecule
- Chemical Formula
- C16H26N2O5S
- CAS Number
- 82009-34-5
- Unique Ingredient Identifier
- 141A6AMN38
- Background
Cilastatin is an inhibitor of renal dehydropeptidase, an enzyme responsible for both the metabolism of thienamycin beta-lactam antibiotics as well as conversion of leukotriene D4 to leukotriene E4. Since the antibiotic, imipenem, is one such antibiotic that is hydrolyzed by dehydropeptidase, cilastatin is used in combination with imipenem to prevent its meta...
- Indication
Cilastatin is indicated, in combination with imipenem with or without relebactam, for the treatment of bacterial infections including respiratory, skin, bone, gynecologic, urinary tract, and intra-abdominal as well as septicemia and endocarditis.
- Associated Conditions
- Bacterial Septicemia, Bone and Joint Infections, Complicated Intra-Abdominal Infections (cIAIs), Complicated Urinary Tract Infection, Endocarditis caused by staphylococcus aureus, Gynecological Infection, Intraabdominal Infections, Lower respiratory tract infection bacterial, Neutropenic Fever, Pyelonephritis, Skin and Subcutaneous Tissue Bacterial Infections, Surgical Site Infections, Uncomplicated Urinary Tract Infections, Hepatic abscess
- Associated Therapies
- -
Spero's stock slides after antibiotic flops in Phase II trial
Spero Therapeutics halted development of antibiotic SPR720 after Phase IIa trial failure in NTM-PD patients, leading to 39% staff layoffs and a 17% stock drop. The company plans to focus on tebipenem HBr and SPR206, with tebipenem HBr out-licensed to GSK.
Related Clinical Trials:
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath